^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Bladder Cancer |
| Drug: | cisplatin (DNA synthesis inhibitor) + paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
NCCN Recommendations for treatment of Muscle-Invasive Bladder Cancer…The following radiosensitizing regimens are recommended: cisplatin plus 5-FU; cisplatin plus paclitaxel; 5-FU plus mitomycin C; and cisplatin alone.
